Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000596683 | SCV000708125 | uncertain significance | not provided | 2017-05-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001337732 | SCV001531344 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2022-08-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002325132 | SCV002606705 | uncertain significance | Cardiovascular phenotype | 2022-09-26 | criteria provided, single submitter | clinical testing | The p.R1116Q variant (also known as c.3347G>A), located in coding exon 26 of the JAG1 gene, results from a G to A substitution at nucleotide position 3347. The arginine at codon 1116 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004553338 | SCV004115464 | uncertain significance | JAG1-related disorder | 2023-11-22 | no assertion criteria provided | clinical testing | The JAG1 c.3347G>A variant is predicted to result in the amino acid substitution p.Arg1116Gln. This variant was reported as uncertain in one individual with asymmetric maculopathy who also carried a variant in ABCA4 gene (Patel et al, Indian J Ophthalmol Case Rep 2021;1:699-701). This variant is reported in 0.0046% of alleles in individuals of European (Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |